Literature DB >> 9298347

Characterization of three human apolipoprotein E isoforms (E2, E3 and E4) expressed in Escherichia coli.

A Barbier1, A Visvikis, F Mathieu, L Diez, L M Havekes, G Siest.   

Abstract

Apolipoprotein E is one of the apolipoproteins involved in cholesterol metabolism. Three major isoforms are present in men: E2, E3, E4 corresponding to the products of three alleles. They have different affinities for receptors and the epsilon 4 allele is a risk factor for cardiovascular diseases and more recently for Alzheimer's disease. We describe here the production, by heterologous expression in Escherichia coli, of the three apolipoprotein E isoforms for use in both research and clinical laboratories. By Surface Plasmon Resonance, the purified recombinant apolipoprotein E isoforms were able to recognize three monoclonal anti-human apolipoprotein E antibodies with affinity constants close to those of purified human apolipoprotein E. For receptor binding studies, the recombinant apolipoprotein E isoforms were associated with VLDL isolated from apolipoprotein E knockout mice. Although the association of the recombinant apolipoproteins E with the mouse VLDL was less efficient than that of human plasma apolipoprotein E3, the recombinant apolipoprotein E3 and apolipoprotein E4 complexes competed efficiently with 125I-labelled LDL for binding to the LDL receptor in J774 macrophages, whereas the recombinant apolipoprotein E2-VLDL complexes did not. These results suggest that the recombinant apolipoprotein E isoforms have biological properties similar to the human apolipoprotein E isoforms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9298347     DOI: 10.1515/cclm.1997.35.8.581

Source DB:  PubMed          Journal:  Eur J Clin Chem Clin Biochem        ISSN: 0939-4974


  1 in total

Review 1.  Surface plasmon resonance for the analysis of beta-amyloid interactions and fibril formation in Alzheimer's disease research.

Authors:  Marie-Isabel Aguilar; David H Small
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.